Cutaneous Adverse Effects of Amivantamab in Patients with Non-Small Cell Lung Cancer
- Author:
Taemin LEE
1
;
Yeon Joo JUNG
;
Sehhoon PARK
;
Hyun Ae JUNG
;
Jong-Mu SUN
;
Jin Seok AHN
;
Myung-Ju AHN
;
Se-Hoon LEE
;
Joonho SHIM
Author Information
1. Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2024;62(5):279-284
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The cutaneous adverse effects (AEs) of amivantamab, a novel monoclonal bispecific antibody against the epidermal growth factor receptor and mesenchymal-epithelial transcription factor, have not been investigated.
Objective:To analyze the type and prevalence of cutaneous AEs in patients with non-small cell lung cancer (NSCLC) treated with amivantamab.
Methods:A single-institution retrospective medical record review was conducted on patients with NSCLC who were treated with amivantamab between January 1, 2021, and June 30, 2023. A total of 37 patients receiving amivantamab monotherapy for NSCLC were included in this study. Demographic data (age, sex, body mass index, age at cancer diagnosis, age at amivantamab therapy initiation, and duration of amivantamab use) and the types and severity of cutaneous AEs were evaluated.
Results:Cutaneous AEs occurred in 59.5% of the patients. The most common AEs were maculopapular eruptions (37.8%), paronychia (24.3%), pruritus/xerosis (16.2%), acneiform eruptions (13.5%), pustulosis (5.4%), and scalp rashes (5.4%). No Grade 3 cutaneous AE, which led to the discontinuation of amivantamab therapy, was observed.
Conclusion:Our data describes an extensive review of cutaneous AEs caused by amivantamab. Further research with a larger patient population is necessary to reliably predict and manage cutaneous AEs associated with amivantamab.
